Last checked at 24 Aug 2020 11:28
NetScientific plc
("NetScientific" or the "Company")
Result of General Meeting
NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, is pleased to announce at its General Meeting held earlier today all resolutions were duly passed.
Accordingly, the Company has today authorised:
1. a capital reorganisation which has the effect of consolidating ten Existing Ordinary Shares into one New Ordinary Share;
2. the issue of 3,538,455 New Ordinary Shares at an Issue Price of 65p pence raising gross proceeds of approximately £2.3 million through a placing (the "Placing") with institutional and other investors;
3. the issue of 3,521,480 New Ordinary Shares to Futura Messis Group Ltd pursuant to the acquisition of EMV Capital Ltd (the "Acquisition"); and
4. The adoption by the Company of the new Articles of Association.
The full details of the Acquisition, Placing and Capital Reorganisation are set out in the announcement dated 5 August 2020.
John Clarkson, Chairman, said "the Board of NetScientific want to express their gratitude to shareholders for their overwhelming vote of support, enabling the transformation of the business, which is now positioned for future success".
Admission to Trading on AIM
Further to the announcement on 5 August 2020, application for admission to trading of the New Ordinary Shares has been made and it is anticipated that admission will take place at 8.00 a.m. on 25 August 2020 ("Admission").
In accordance with the provisions of the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority, the Company confirms that, following the Acquisition, Placing and Capital Reorganisation, its issued share capital will comprise 14,916,122 New Ordinary Shares upon Admission. All of these New Ordinary Shares have equal voting rights and none of the New Ordinary Shares are held in treasury. The total number of voting rights in the Company will therefore be 14,916,122 upon Admission.
Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the announcement dated 5 August 2020.
The full details of the votes cast are as follows.
Votes Cast | % of Votes Cast | |||||
Resolution No. | Resolution Text | For | Against | For | Against | |
Special Resolution 1 | To adopt the new Articles of Association of the Company | 23,518,025 | 421,879 | 98.2% | 1.8% | |
Ordinary Resolution 2 | To approve the proposed sub-division | 23,508,223 | 431,681 | 98.2% | 1.8% | |
Ordinary Resolution 3 | To approve the proposed consolidation | 23,511,134 | 428,770 | 98.2% | 1.8% | |
Ordinary Resolution 4 | To approve the waiver granted by the Panel on Takeovers and Mergers of any requirement under Rule 9 on the Concert Party to make a general offer to shareholders | 23,513,842 | 425,777 | 98.2% | 1.8% | |
Ordinary Resolution 5 | To authorise the Directors to allot shares in the Company in respect of the Consideration and Placing Shares | 23,446,323 | 493,581 | 97.9% | 2.1% | |
Ordinary Resolution 6 | To authorise the Directors to allot shares in the Company generally | 23,446,038 | 493,581 | 97.9% | 2.1% | |
Special Resolution 7 | To disapply statutory pre-emption rights in respect of the Placing Shares | 23,446,038 | 493,581 | 97.9% | 2.1% | |
Special Resolution 8 | To disapply statutory pre-emption rights generally | 23,446,038 | 493,581 | 97.9% | 2.1% | |
# # #
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Following the publication of this announcement, this inside information is now considered to be in the public domain.
For more information, please contact:
NetScientific
Ilian Iliev, CEO Tel: +44 (0)20 3514 1800
WH Ireland (NOMAD, Financial Adviser and Broker)
Chris Fielding / Jessica Cave / Darshan Patel Tel: +44 (0)20 7220 1666
MO PR ADVISORY (Press Contact)
Mo Noonan Tel: +44 (0)78 7644 4977
About NetScientific
NetScientific PLC is a transatlantic healthcare IP commercialisation Group focused on technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people.
For more information, please visit the website at www.NetScientific.net